Salient Features of IP-2010 (VI edition)

Similar documents
General concepts in the Ph. Eur.: theory and rationale

Japanese Pharmacopoeia s Challenge to the Globalization

Annex 1. Good pharmacopoeial practices

CONCEPT PAPER FOR COMMENT

Product Permission Document (PPD) of Typhoid Polysaccharide Vaccine I.P. (Brand Name Bio-Typh TM )

TABLE OF CONTENTS. 1. Introduction

The European Pharmacopoeia

A.1 Contents file 4 to 5 A.1 (1)

Implementation of the ICH Q3D guideline in the Ph. Eur.

Changes in European Endotoxin Testing Regulations and Guidance By Mick Dawson

International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW

GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs)

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

English only/anglais seulement PA/PH/CEP (15) 31. Certification of suitability to the Monographs of the European Pharmacopoeia.

A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999

European Pharmacopoeia Reference Standards A Lodi, Head of the Laboratory Department, EDQM, Council of Europe

GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET

European Medicines Agency Evaluation of Medicines for Human Use

Draft agreed by Quality Working Party 7 June Adopted by CHMP for release for consultation 28 June 2018

Quality of Active Pharmaceutical Ingredients In collaboration with EMEA, EDQM, EU, FDA & WHO

Pharmaceutical product technical requirements and the Interagency pharmaceutical product questionnaire

Consultation response: Dissolution testing in BP finished products monographs for solid oral dosage forms

Question-based Review (QbR)

Registration of. Proprietary Chinese Medicine!

Guidelines for Pharmaceutical Equivalence Requirements

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: MANUFACTURE OF THE FINISHED DOSAGE FORM

Stability testing for medicinal products prepared in accordance with homoeopathic manufacturing procedures

European Regulations for Medicines Place and Role of the EDQM and the European Pharmacopoeia

LEGAL REQUIREMENTS FOR STABILITY

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON SUMMARY OF REQUIREMENTS FOR ACTIVE SUBSTANCES IN PART II OF THE DOSSIER

Product Permission Document (PPD) of Meningococcal Polysaccharide A & C Vaccine I.P.

1225 Eye Street NW, Ste. 400 Washington, DC 20005

Name of Chapter & Details. Section-I

Manual 055 Commercial Stability Testing For Formulated Products. This procedure applies to all drug products. The procedure covers:

EudraLex. Part I1 Chapter 6: Quality Control

On the Q&A to the Guideline for Common Technical Documents

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES

Session 5: Increase in Use of the WHO Prequalification Programme

ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon

GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE IA AND TYPE IB NOTIFICATIONS July 2003

Technical Guide. vaccines and other immunological human medicinal products. for the elaboration of monographs on. European Pharmacopoeia

GENERAL PHARMACOPOEIA MONOGRAPH

Product Permission Document (PPD) of Haemophilus type b Conjugate Vaccine I.P. (Brand Name Peda Hib )

SPECIFIC MONOGRAPHS. A Guide Through The Different Sections. Claude Coune

Guidance for Industry

CURRENT CHALLENGES IN GLOBAL REGULATORY COMPLIANCE QUALITY OF PHARMACEUTICAL INGREDIENTS PHARMACOPOEIAL HARMONISATION PROCESS

WHO guidelines on variations to a prequalified product

Content of the dossier for chemical purity and microbiological quality

MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

DRUGS DIRECTORATE GUIDELINES PREPARATION OF DRUG IDENTIFICATION NUMBER SUBMISSIONS

European Directorate for the Quality of Medicines & HealthCare (EDQM)

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE

REGULATION (EC) No 542/95

ICH 교육가이드라인 [ 안전성 & 품질 ]

DIDANOSINE ORAL POWDER Final text for addition to The International Pharmacopoeia

Working document QAS/11.415/Rev. 1 August 2011 RESTRICTED DRAFT FOR COMMENT

Annex 4. Model certificate of analysis

EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016

How the European Pharmacopoeia Provides the Framework to Implement QbD Principles

Guidance Document 01 January 2016 CONTENTS. 1. Introduction Background 1.2. Objectives 1.3. Scope and application 1.4 APIMF holder obligations

How to build a good CEP application - ICH Q3D

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE:

Wirkstoffdokumentation & CEP- Verfahren

Working document QAS/ June 2011 RESTRICTED DRAFT FOR COMMENT

The European Approach on Large Sample Sizes in the context of a PAT Environment

5. Changes to a CEP or to a confirmation of API-prequalification document 106

Guideline on requirements for the production and control of immunological veterinary medicinal products

Validation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness

á232ñ ELEMENTAL IMPURITIES LIMITS

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials

Technical guide for the ELABORATION AND USE OF MONOGRAPHS ON HUMAN PLASMA- DERIVED PRODUCTS

Elemental impurities Expectations for APIs and Excipients in the EU

QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

Materials Management Traceability, CEPs and managing non-conforming sites

Official Letter from the DOH

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex

Guide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides

Guide to the investigational medicinal product dossier

ADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH

CMC Strategy Forum, Paris 2008

Journal of Chemical and Pharmaceutical Research

EDQM Overview of our products and services

Proposals for the Guideline on Classification of Variations. Only those variations applicable to the active substance are listed.

Equipment cleaning and use record

WHO DRAFT PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS

VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)

Identification of the need and uses of a reference standard

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

1-6 Specifications. Andrew Chemwolo, Technical Officer, WHO Prequalification Team Medicines Assessment

GUIDELINES ON FORMAT AND CONTENT OF LABELS FOR MEDICINAL PRODUCTS

Product Permission Document (PPD) of Typhoid Vi Conjugate Vaccine I.P. (Brand Name Peda Typh TM )

Transcription:

Salient Features of IP-2010 (VI edition) By:- Dr. Raman Mohan Singh Principal Scientific Officer, IPC-IPL, IPL, Ghaziabad. Website: www.ipc.gov.in Email: ipclab@vsnl.net

As per the Drugs and Cosmetics Act 1940, the Indian Pharmacopoeia is the legally recognized book of Standards for the quality of drug substances and preparations included therein.

Introduction This new edition of the Indian Pharmacopoeia entitled Indian Pharmacopoeia 2010 has been prepared by the Indian Pharmacopoeia Commission (IPC) in accordance with a plan and completed through the untiring efforts of its members, Secretariat and Laboratory over a period of about two years.

This is the sixth edition of the Indian Pharmacopoeia after Independence. It supersedes the 2007 edition but any monograph of the earlier edition that does not figure in this edition continues to be official as stipulated in the Second Schedule of the Drugs and Cosmetics Act, 1940.

Publication of IP Edition Year I 1955 II 1966 III 1985 IV 1996 Addenda - 2000 2000 (Vet. Suppl) 2002 2005 V 2007 Addendum - 2008 VI New Edition- 2010

Publication and Printing Published by : Indian Pharmacopoeia Commission, Ghaziabad. Printed by : National Institute of Science Communication And Information Resources (NISCAIR) near Pusa Gate, New Delhi.

Presentation of IP 2010 IP 2010 is presented in three volumes with the following features: Volume 1 Volume 2 Volume 3

Content of Volume I Notices Preface Indian Pharmacopoeia Commission Acknowledgements Introduction General Chapters o General Notices o Test Methods o Apparatus

o Biological Methods o Chemical Methods o Physical and Physicochemical Methods o Pharmaceutical Methods o Tests on Herbal Products o Tests on Vaccines o Tests on Blood and Blood-related Products o Reference Data o Reagents and Solutions o General Tests o Containers o Tables

Content of Volume II General Notices General Monographs on Dosage Forms Monographs on Drug substances, Dosage forms and Pharmaceutical Aids Monographs A to M

Content of Volume III General Notices Monographs on Drug substances, Dosage forms and Pharmaceutical aids Monographs N to Z Monographs on Vaccines and Immunosera for Human Use Monographs on Herbs and Herbal Products Monographs on Blood and Blood-related Products

Monographs on Biotechnology Products Monographs on Veterinary Products o Non-Biological o Biological o Diagnostics Index

NEW EDITION New Drugs API s Formulations Anticancer drugs Excipients Vaccines and Other Biological Products Herbal Products

Specific features Adding: (i) New monographs. (ii) Category, Dose and Usual Strengths. (iii) General Chapter on Liposomal Preparations. (iv) Appendices on NMR. (v) New Herbs and Herbal monographs.

(vi) Excipient monographs. (vii) Anticancer monographs. (viii) Adopted for latest drug delivery system (i.e. Amphotericin B Injection). (ix) Drugs not in use are omitted from this edition.

The scope of the Pharmacopoeia has been extended to include products of biotechnology, indigenous herbs and herbal products, Veterinary vaccines and additional antiretroviral drugs and formulations, inclusive of commonly used fixed-dose dose combinations. Standards for new drugs and drugs used under National Health Programmes are added in this edition and drugs as well as their formulations not in use now a days are omitted from this edition. GNS-IPC IPC-GZB 16

The number of monographs of Excipients, Anticancer drugs, Herbal products and Anti HIV drugs have been increased in this edition. Monographs of Vaccines and Immunosera are also upgraded in view of latest technology in the field. A new chapter on Liposomal products and a monograph of Liposomal Amphotericin B injection is an added advantage in veiw of latest technology adopted for drug delivery. GNS-IPC IPC-GZB 17

A chapter on NMR is also incorporated in Appendices. The chapter on microbial contamination is also updated to great extent to harmonize with prevailing international scenario.

Format In an effort to make the pharmacopoeia more user-friendly, design of the texts of the monographs and of the test methods are kept same however they are upgraded. Cross-referencing referencing has been avoided to make each monograph complete in itself thus making it convenient to the analyst performing the tests and to the ones checking the results of analysis. GNS-IPC IPC-GZB 19

Basis of Pharmacopoeial requirement As in the past, this compendium provides a publicly available statement concerning the quality of a product that can be expected and demonstrated at any time throughout the accepted shelf-life life of the article. The standards laid down represent the minimum with which the article must comply and it is incumbent on the manufacturer to ensure that the article is manufactured in accordance with Good Manufacturing Practices (GMPs). GNS-IPC IPC-GZB 20

It is essential that sufficiently stringent limits are applied at the time of release of a batch of a material or product so that the pharmacopoeial standards are met until its expiry date under the storage conditions specified. It must be noted that a valid interpretation of any requirement of the Pharmacopoeia should be done in the context of the monograph as a whole, the relevant general monograph, where appropriate, the specified tests and methods of analysis including any reference to the relevant General Notices.

Familiarity with the General Notices will facilitate the correct application of the requirements. GNS-IPC IPC-GZB 22

Changes Keeping in view the essential requirement under the Drugs and Cosmetics Act, 1940 and Rules there in the information on category of a drug, dosage and usual available strengths of dosage forms has been re-kept in this edition. General chemical tests for identification of an article have been almost eliminated and the more specific infrared and ultraviolet spectrophotometric tests have been given emphasis. The concept of relying on published infrared spectra as a basis for identification has been continued. GNS-IPC IPC-GZB 23

The use of chromatographic methods has been greatly extended to cope with the need for more specificity in assays and in particular, in assessing the nature and extent of impurities in ingredients and products. Most of existing Assays and Related substances tests are upgraded by liquid chromatographic method in view to harmonize with other international Pharmacopoeias. GNS-IPC IPC-GZB 24

The test for pyrogens involving the use of animals has been virtually eliminated. The test for bacterial endotoxins introduced in the previous editions is now applicable to more items. The test for abnormal toxicity is now confined to certain vaccines. GNS-IPC IPC-GZB 25

General Chapters Volume I is devoted mainly to test methods that are applicable to all the articles of the pharmacopoeia and general information pertaining to the quality requirements of medicinal substances. It also includes reference data such as reference spectra, typical chromatograms etc. GNS-IPC IPC-GZB 26

The test methods reflect the sophistication of analytical methodology and instrumentation. Analytical methods are in general in harmony with those adopted internationally for monitoring the quality of drugs. The steps taken for harmonization have been initiated by the need to cope with the increasing demand for drugs manufactured in the country to globally accepted standards. GNS-IPC IPC-GZB 27

The trend towards controlling the microbial quality of all medicinal products has been recognized and the requirement regarding limits of bacterial contamination even of products for oral administration and topical application so that adequate controls are exercised by manufacturers by the adoption of GMPs has been continued. GNS-IPC IPC-GZB 28

General Monographs The General Monographs for dosage forms of active pharmaceutical ingredients (APIs) are grouped together at the beginning of Volume II. They are followed by the monographs for the APIs, pharmaceutical aids and individual dosage forms, all in alphabetical order. Monographs for other articles of a special GNS-IPC IPC-GZB 29

nature such as vaccines and immunosera for human use, herbs and herbal products, blood and blood related products, biotechnology products and veterinary products are given in separate sections in Volume III.